Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Authors
Keywords
-
Journal
BLOOD
Volume 135, Issue 6, Pages 399-410
Publisher
American Society of Hematology
Online
2019-12-20
DOI
10.1182/blood.2019000621
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy
- (2019) Jianming Wu et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
- (2018) Andreas T. Björklund et al. CLINICAL CANCER RESEARCH
- Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells
- (2018) Katja Srpan et al. JOURNAL OF CELL BIOLOGY
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy
- (2018) Huang Zhu et al. STEM CELLS
- Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells
- (2018) Michelle L. Saetersmoen et al. Seminars in Immunopathology
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- NK cell-based immunotherapy for cancer
- (2017) Fang Fang et al. SEMINARS IN IMMUNOLOGY
- A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
- (2017) Brent A. Williams et al. Oncotarget
- Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications
- (2017) Anushruti Sarvaria et al. Frontiers in Immunology
- Exploitation of natural killer cells for the treatment of acute leukemia
- (2016) Rupert Handgretinger et al. BLOOD
- Off the shelf cellular therapeutics: Factors to consider during cryopreservation and storage of human cells for clinical use
- (2016) Erik J. Woods et al. CYTOTHERAPY
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
- (2016) Hans Klingemann et al. Frontiers in Immunology
- Clinical manufacturing of CAR T cells: foundation of a promising therapy
- (2016) Xiuyan Wang et al. Molecular Therapy-Oncolytics
- The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
- (2015) M. Rosario et al. CLINICAL CANCER RESEARCH
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
- (2015) David L. Hermanson et al. STEM CELLS
- Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
- (2015) Mattias Carlsten et al. Frontiers in Immunology
- Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity
- (2015) Carin I. M. Dahlberg et al. Frontiers in Immunology
- Identification of an ADAM17 Cleavage Region in Human CD16 (FcγRIII) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells
- (2015) Yawu Jing et al. PLoS One
- Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
- (2014) V. Bachanova et al. BLOOD
- FcγRIII (CD16)-mediated ADCC by NK cells is regulated by monocytes and FcγRII (CD32)
- (2014) Nupur Bhatnagar et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Effect of tumor cells and tumor microenvironment on NK-cell function
- (2014) Massimo Vitale et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
- (2014) Y. Chu et al. Cancer Immunology Research
- Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells
- (2014) Bahram Valamehr et al. Stem Cell Reports
- NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
- (2013) R. Romee et al. BLOOD
- Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In Vivo
- (2013) Zhenya Ni et al. STEM CELLS
- Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy
- (2013) David A. Knorr et al. Stem Cells Translational Medicine
- ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils
- (2012) Yue Wang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
- (2012) Cecele J. Denman et al. PLoS One
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
- (2011) M. R. Parkhurst et al. CLINICAL CANCER RESEARCH
- A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
- (2010) Eleni G. Iliopoulou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of Mature ADAM17 by Redox Agents for L-Selectin Shedding
- (2009) Y. Wang et al. JOURNAL OF IMMUNOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Up on the tightrope: natural killer cell activation and inhibition
- (2008) Lewis L Lanier NATURE IMMUNOLOGY
- Targeting EGFR in Colorectal Cancer
- (2008) Wells A. Messersmith et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now